AI-Powered Heart Failure Detection Technology Recognized Among Asia-Pacific’s Top 20 MedTech Startups
Simplex Quantum, a Tokyo-based medical technology startup specializing in AI-driven heart health solutions, has been selected as one of 20 high-potential startups for the prestigious MedTech Innovator Asia Pacific 2025 Accelerator Program.
Health Technology Insights: enGene Names Amy Pott as Chief Global Commercialization Officer
MedTech Innovator is the world’s largest accelerator of medical technology companies, aiming to improve human health by accelerating the growth of companies transforming patient care. The Asia Pacific program connects best-in-class startups with investors, business leaders, and service professionals in the medtech industry to drive the commercialization of life-changing technologies in the region.
This year, over 550 companies applied for the Asia Pacific program. After a rigorous selection process, 60 companies were invited to pitch, and 20 were chosen for the 2025 cohort. The selected companies will participate in a four-month accelerator program, culminating in the MedTech Innovator Asia Pacific Showcase and Grand Finals in Singapore at the end of October.
Health Technology Insights: Todata Launches SiteGrades to Boost Clinical Site Performance
“We are honored to be part of the MedTech Innovator Asia Pacific 2025 cohort,” said Ryu Saito, CEO of Simplex Quantum. “This opportunity validates our commitment to transforming heart failure detection and management with scalable, AI-driven solutions. We look forward to leveraging this platform to forge strategic partnerships and expand our impact across Asia and beyond.”
Revolutionizing Heart Failure Detection with AI
Simplex Quantum’s flagship technology, NIHA-HF (Neural Intelligent Heart Analyzer – Heart Failure), enables early detection of heart failure using a 30-second, single-lead ECG analyzed through advanced neural networks. Unlike traditional methods that require costly imaging or invasive monitoring, NIHA-HF is designed to be integrated into clinical 12-lead ECG systems and consumer-accessible wearables. NIHA-HF has been granted patents in Japan, the United States, and India, and is currently progressing through regulatory pathways in both Japan (PMDA) and the United States (FDA).
NIHA-HF is an investigational device and is not yet approved by the U.S. FDA or Japan PMDA.
Health Technology Insights: Eden Appoints Dr. Halland Chen, MD as Chief Medical Innovation Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
